• Ethan D Borre, Judy R Dubno, Evan R Myers, Susan D Emmett, Juliessa M Pavon, Howard W Francis, Osondu Ogbuoji, and Gillian D Sanders Schmidler.
• Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
• J Gen Intern Med. 2023 Mar 1; 38 (4): 978985978-985.

BackgroundWhile 60% of older adults have hearing loss (HL), the majority have never had their hearing tested.ObjectiveWe sought to estimate long-term clinical and economic effects of alternative adult hearing screening schedules in the USA.DesignModel-based cost-effectiveness analysis simulating Current Detection (CD) and linkage of persons with HL to hearing healthcare, compared to alternative screening schedules varying by age at first screen (45 to 75 years) and screening frequency (every 1 or 5 years). Simulated persons experience yearly age- and sex-specific probabilities of acquiring HL, and subsequent hearing aid uptake (0.5-8%/year) and discontinuation (13-4%). Quality-adjusted life-years (QALYs) were estimated according to hearing level and treatment status. Costs from a health system perspective include screening ($30-120; 2020 USD), HL diagnosis ($300), and hearing aid devices ($3690 year 1, $910/subsequent year). Data sources were published estimates from NHANES and clinical trials of adult hearing screening.ParticipantsForty-year-old persons in US primary care across their lifetime.InterventionAlternative screening schedules that increase baseline probabilities of hearing aid uptake (base-case 1.62-fold; range 1.05-2.25-fold).Main MeasuresLifetime undiscounted and discounted (3%/year) costs and QALYs and incremental cost-effectiveness ratios (ICERs).Key ResultsCD resulted in 1.20 average person-years of hearing aid use compared to 1.27-1.68 with the screening schedules. Lifetime total per-person undiscounted costs were $3300 for CD and ranged from $3630 for 5-yearly screening beginning at age 75 to $6490 for yearly screening beginning at age 45. In cost-effectiveness analysis, yearly screening beginning at ages 75, 65, and 55 years had ICERs of $39,100/QALY, $48,900/QALY, and $96,900/QALY, respectively. Results were most sensitive to variations in hearing aid utility benefit and screening effectiveness.LimitationInput uncertainty around screening effectiveness.ConclusionsWe project that yearly hearing screening beginning at age 55+ is cost-effective by US standards.© 2022. The Author(s), under exclusive licence to Society of General Internal Medicine.

15 keywords...

hide…